Petros Pharmaceuticals EBIT

Petros Pharmaceuticals (PTPI) currently reports a EBIT of $-4.6B as of June 2026. That compares with $-2.4B in the prior-year period — down 94.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Petros Pharmaceuticals's EBIT history and peer comparisons.

Petros Pharmaceuticals's EBIT decreased from $-2.4B to $-4.6B — a 94.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Petros Pharmaceuticals's EBIT of $-4.6B is lower than the Healthcare sector average of $23B. That is roughly 120.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Petros Pharmaceuticals reported $-4.6B in EBIT as of June 2026. That compares with $-2.4B in the prior-year period — down 94.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-4.6B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Petros Pharmaceuticals, and consider following PTPI for alerts when major investors trade the stock.